TZPD is a dual GIP and GLP-1 receptor agonist that provides significant benefits for type 2 diabetes, chronic weight management, and related cardiometabolic conditions.
Improved blood sugar control: Significantly lowers HbA1c levels, it increases insulin release, reduces sugar production in the liver, and slows digestion to help regulate blood glucose.
Reduced risk of progression: In individuals with pre-diabetes and obesity, studies have shown that it can reduce the risk of progressing to type 2 diabetes by over 90%.
Enhanced insulin sensitivity: The medication helps the body use insulin more effectively, a key benefit for people with insulin resistance.
Significant weight reduction: It has been shown that patients can lose a substantial amount of weight. It can achieve a 20% or more reduction in their body weight.
Effective appetite regulation: Acts on brain centers to reduce feelings of hunger and increase feelings of fullness, which helps lower overall food intake.
Reduces health risks: Sustainable weight loss reduces health risks associated with obesity, such as high blood pressure, sleep apnea, and joint pain.
Reduced heart failure risk: For obese patients with heart failure with preserved ejection fraction, TZPD has been shown to reduce the risk of hospitalization or death from heart failure.
Improved heart function: The drug improves heart failure symptoms, health status, and exercise tolerance.
Favorable lipid profile: It can improve cholesterol levels by lowering total cholesterol, LDL (“bad”) cholesterol, and triglycerides while increasing HDL (“good”) cholesterol.
Lowered blood pressure: Studies have shown that it can help reduce both systolic and diastolic blood pressure.
Reviews
There are no reviews yet.